Show simple item record

dc.contributor.authorBradshaw, CS
dc.contributor.authorChen, MY
dc.contributor.authorFairley, CK
dc.date.accessioned2021-02-04T02:05:05Z
dc.date.available2021-02-04T02:05:05Z
dc.date.issued2008-11-03
dc.identifier.citationBradshaw, C. S., Chen, M. Y. & Fairley, C. K. (2008). Persistence of Mycoplasma genitalium Following Azithromycin Therapy. PLOS ONE, 3 (11), https://doi.org/10.1371/journal.pone.0003618.
dc.identifier.issn1932-6203
dc.identifier.urihttp://hdl.handle.net/11343/259566
dc.description.abstractBACKGROUND: To determine clinical outcomes and cure rates for M.genitalium genital infection in men and women following azithromycin 1 g. METHODOLOGY: Patients attending Melbourne Sexual Health Centre between March 2005 and November 2007 with urethritis/epididymitis, cervicitis/pelvic inflammatory disease and sexual contacts of M.genitalium were tested for M.genitalium by polymerase chain reaction (PCR). M.genitalium-infection was treated with 1 g of azithromycin and a test-of-cure (toc) was performed one month post-azithromycin. Response to azithromycin, and response to moxifloxacin (400 mg daily for 10 days) in individuals with persistent infection post-azithromycin, was determined. PRINCIPAL FINDINGS: Of 1538 males and 313 females tested, 161 males (11%) and 30 females (10%) were infected with M.genitalium. A toc was available on 131 (69%) infected individuals (median = 36 days [range 12-373]). Of 120 individuals prescribed azithromycin only pre-toc, M.genitalium was eradicated in 101 (84%, 95% confidence intervals [CI]: 77-90%) and persisted in 19 (16%, 95% CI: 10-23%). Eleven individuals with persistent infection (9%, 95% CI: 5-15%) had no risk of reinfection from untreated-partners, while eight (7%, 95% CI: 3-12%) may have been at risk of reinfection from doxycycline-treated or untreated-partners. Moxifloxacin was effective in eradicating persistent infection in all cases not responding to azithromycin. Patients with persistent-M.genitalium were more likely to experience persistent symptoms (91%), compared to patients in whom M.genitalium was eradicated (17%), p<0.0001. CONCLUSION: Use of azithromycin 1 g in M.genitalium-infected patients was associated with unacceptable rates of persistent infection, which was eradicated with moxifloxacin. These findings highlight the importance of follow-up in M.genitalium-infected patients prescribed azithromycin, and the need to monitor for the development of resistance. Research to determine optimal first and second-line therapeutic agents for M.genitalium is needed.
dc.languageEnglish
dc.publisherPUBLIC LIBRARY SCIENCE
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titlePersistence of Mycoplasma genitalium Following Azithromycin Therapy
dc.typeJournal Article
dc.identifier.doi10.1371/journal.pone.0003618
melbourne.affiliation.departmentUniversity General
melbourne.affiliation.departmentMelbourne School of Population and Global Health
melbourne.affiliation.facultyUniversity Services
melbourne.affiliation.facultyMedicine, Dentistry & Health Sciences
melbourne.source.titlePLoS One
melbourne.source.volume3
melbourne.source.issue11
dc.rights.licenseCC BY
melbourne.elementsid1215827
melbourne.contributor.authorChen, Marcus
melbourne.contributor.authorFairley, Christopher
dc.identifier.eissn1932-6203
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record